Comparison · NCT01186003-a9a2ef83
Standard Insulin Drip Therapy vs Insulin Drip and Detemir: Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard Insulin Drip Therapy vs Insulin Drip and Detemir: Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl). Trial comparisons, record NCT01186003-a9a2ef83. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01186003-a9a2ef83
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.785 | 1 | wilson | |
| Risk in group 2 | 0.188 | 0.0659 | 0.43 | wilson | |
| Risk difference, group 1 minus group 2 | 0.813 | 0.488 | 0.934 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 5.33 | 1.92 | 14.8 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Standard Insulin Drip Therapy than on Insulin Drip and Detemir | 1.23 | 1.07 | 2.05 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard Insulin Drip Therapy | Continuous IV insulin infusion without added detemir | 14 | 14 | OG000 |
| Group 2 | Insulin Drip and Detemir | Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy | 3 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl)
- Description
- Number of participants exhibiting rebound hyperglycemia (blood glucose levels over 180 mg/dl)
- Time frame
- within 48 hours of discontinuation
- Population
Source ClinicalTrials.gov
Trial
- Title
- Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
- NCT number
- NCT01186003
- Phases
- NA
- Conditions
- Diabetes
- Interventions
- Detemir
- Lead sponsor
- University of Colorado, Denver
- Results first posted
- 2021-12-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01186003?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01186003-a9a2ef83